NLAB Silica Technology

NLAB Silica Technology

In the Drug Delivery business area, Nanologica develops nanoporous silica, NLAB SilicaTM, for the improved delivery of Active Pharmaceutical Ingredients (APIs) in oral dosage form. Up to 90% of oral medicines in development today suffer from low oral solubility. This can compromise the efficacy and safety of new drug compounds leading to poor patient response and prohibit further drug development. Nanologica uses its extensive knowledge of interactions between APIs and the materials in its broad NLAB SilicaTM portfolio in order to develop new pharmaceutical formulations with dramatic improvement in solubility, stability and handling.

Case Studies – 1

Reformulated drugs with improved efficacy

NLAB SilicaTM has shown great potential for tackling one of the most pressing global issues of multi resistant bacteria which, according to the World Health Organization (WHO), is a major threat to worldwide public health. Nanologica developed new formulations of marketed anti-infective drugs to overcome complications and limitations of the drugs. The studies demonstrated that the reformulated drugs can lead to improved efficacy and safety compared to the current products. Reformulation of pharmaceutical drugs using NLAB SilicaTM offers an effective route to provide better oral treatment to help combat infectious diseases, such as antibiotic-resistant tuberculosis or HIV.

Case Studies – 2

A milestone has successfully been achieved using NLAB SilicaTM as the delivery vehicle for biologics formulation. Peptide growth factors were encapsulated in NLAB SilicaTM to enable controlled and sustained release upon transplantation in vivo. The controlled delivery of growth factors resulted in improved differentiation and survival of co-transplanted neuron stem cells in mouse models of spinal cord injury and other neuronal diseases. These findings have the potential of revolutionizing the treatment of neurodegenerative disorders. Nanologica is presently pursuing results from this research towards Amyotrophic lateral sclerosis (ALS) therapy.

Clinical Benefits

Silica-based technology has multiple competitive advantages over alternative delivery technologies. Additionally, NLAB SilicaTM is unique in its controlled pore size, particle size and particle size distribution.

Publications

Nanologica maintains strong fundamental research activities validating applications of porous silica for drug delivery. We routinely publish scientific studies in peer-reviewed journals.

Patents

Nanologica has a strong patent portfolio based on its proprietary material and applications in drug delivery.

Select your currency
EUR Euro